Viridian Therapeutics

Historical price data

Viridian Therapeutics is dedicated to framing the future of autoimmune disease treatment by developing optimized therapeutics for rare conditions. The company's core strategy centers on its antibody discovery and engineering platform, with a lead focus on Thyroid Eye Disease (TED) and a broader portfolio targeting the neonatal Fc receptor (FcRn). As a public company, Viridian is advancing its clinical-stage pipeline with the goal of improving patient care in areas of high unmet medical need.

Antibody discovery and engineering platform focused on developing optimized monoclonal antibodies, with a core expertise in targeting the neonatal Fc receptor (FcRn) to reduce pathogenic autoantibodies.

8 drugs in pipeline, 8 in Phase 3

Viridian faces direct competition in Thyroid Eye Disease from Horizon/Amgen's Tepezza. In the broader FcRn inhibitor space, it competes with argenx, UCB, and Johnson & Johnson. Differentiation is sought through antibody optimization for potentially improved dosing, safety, or efficacy profiles.